共 50 条
Iron deficiency and iron deficiency anaemia in women
被引:81
|作者:
Percy, Laura
[1
]
Mansour, Diana
[2
]
Fraser, Ian
[3
]
机构:
[1] New Croft Ctr, ST Community Sexual & Reprod Healthcare 6, Market St East, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England
[2] New Croft Ctr, Community Gynaecol & Reprod Healthcare, Market St East, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England
[3] Univ New South Wales, Royal Hosp Women, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
关键词:
iron deficiency;
iron deficiency anaemia;
anaemia;
heavy menstrual bleeding;
hepcidin;
QUALITY-OF-LIFE;
ORAL IRON;
HEALTH;
D O I:
10.1016/j.bpobgyn.2016.09.007
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
Iron deficiency (ID) is the most common micronutrient deficiency worldwide with >20% of women experiencing it during their reproductive lives. Hepcidin, a peptide hormone mostly produced by the liver, controls the absorption and regulation of iron. Understanding iron metabolism is pivotal in the successful management of ID and iron deficiency anaemia (IDA) using oral preparations, parenteral iron or blood transfusion. Oral preparations vary in their iron content and can result in gastrointestinal side effects. Parenteral iron is indicated when there are compliance/tolerance issues with oral iron, comorbidities which may affect absorption or ongoing iron losses that exceed absorptive capacity. It may also be the preferred option when rapid iron repletion is required to prevent physiological decompensation or given preoperatively for non-deferrable surgery. As gynaecologists, we focus on managing women's heavy menstrual bleeding (HMB) and assume that primary care clinicians are treating the associated ID/IDA. We now need to take the lead in diagnosing, managing and initiating treatment for ID/IDA and treating HMB simultaneously. This dual management will significantly improve their quality of life.
引用
收藏
页码:55 / 67
页数:13
相关论文